Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.

Diverging from typical approaches that focus on damaged neurons, Neuvivo's drug addresses ALS as an immune system disorder. By supplying a molecule the immune system is missing, it helps regulate the system, allowing the body to recover from the attacks that cause neurodegeneration.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.

While T-regs are most commonly associated with autoimmune conditions, Coya focuses on neurodegeneration. This strategy is based on their founder's research showing T-reg dysfunction is a major driver of diseases like ALS and FTD, applying a known biological mechanism to a novel, high-unmet-need therapeutic area.

The company's strategic goal is not a cure but to slow the underlying progression of Parkinson's. By reducing toxic lipids and protecting neurons, the aim is to decelerate the disease's advancement so significantly that patients can effectively outlive its most severe impacts. This reframes the value proposition for a neurodegenerative disease.